Catalyst Pharmaceuticals Stock Fundamentals
| CPRX Stock | USD 21.02 0.15 0.72% |
Catalyst Pharmaceuticals fundamentals help investors to digest information that contributes to Catalyst Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Catalyst Stock. The fundamental analysis module provides a way to measure Catalyst Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Catalyst Pharmaceuticals stock.
Catalyst |
Catalyst Pharmaceuticals Company Operating Margin Analysis
Catalyst Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Catalyst Pharmaceuticals Operating Margin | 0.44 % |
Most of Catalyst Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Catalyst Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Catalyst Pharmaceuticals has an Operating Margin of 0.4431%. This is 101.26% lower than that of the Biotechnology sector and 100.4% lower than that of the Health Care industry. The operating margin for all United States stocks is 108.04% lower than that of the firm.
Catalyst Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Catalyst Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Catalyst Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Catalyst Pharmaceuticals competition to find correlations between indicators driving Catalyst Pharmaceuticals's intrinsic value. More Info.Catalyst Pharmaceuticals is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Catalyst Pharmaceuticals is roughly 1.59 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Catalyst Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Catalyst Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Catalyst Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Catalyst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Catalyst Pharmaceuticals by comparing valuation metrics of similar companies.Catalyst Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Catalyst Fundamentals
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.44 % | ||||
| Current Valuation | 2.06 B | ||||
| Shares Outstanding | 121.45 M | ||||
| Shares Owned By Insiders | 6.30 % | ||||
| Shares Owned By Institutions | 82.79 % | ||||
| Number Of Shares Shorted | 5.72 M | ||||
| Price To Earning | 23.62 X | ||||
| Price To Book | 3.54 X | ||||
| Price To Sales | 5.15 X | ||||
| Revenue | 491.73 M | ||||
| Gross Profit | 421.11 M | ||||
| EBITDA | 195.12 M | ||||
| Net Income | 163.89 M | ||||
| Cash And Equivalents | 220.79 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 2.79 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 6.02 X | ||||
| Cash Flow From Operations | 143.6 M | ||||
| Short Ratio | 5.95 X | ||||
| Earnings Per Share | 1.31 X | ||||
| Target Price | 33.33 | ||||
| Number Of Employees | 181 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 2.53 B | ||||
| Total Asset | 851.41 M | ||||
| Retained Earnings | 285.16 M | ||||
| Working Capital | 502.93 M | ||||
| Current Asset | 59.9 M | ||||
| Current Liabilities | 3.44 M | ||||
| Net Asset | 851.41 M |
About Catalyst Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Catalyst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.